HCG 10000 IU Review

Human chorionic gonadotropin (hCG) occupies a singular position in the pharmacology of glycoprotein hormones. It is simultaneously one of the oldest clinically characterized gonadotropins, one of the most structurally complex peptide therapeutics ever purified, and one of the most pharmacologically informative tools available to researchers studying luteinizing hormone receptor (LHCGR) biology, Leydig cell physiology, and corpus luteum function. The 10,000 IU vial format offered by Apollo Peptide Sciences positions this compound for laboratory investigations where a large, discrete-dose aliquot is operationally convenient, and where the prolonged half-life of hCG relative to recombinant LH makes it preferable for certain in vitro and in vivo research designs.

This review synthesizes the structural biochemistry, receptor pharmacology, published efficacy data, pharmacokinetic parameters, and quality-assurance considerations relevant to researchers working with hCG 10000 IU. The article is organized to move from molecular identity through mechanism, then into the published research base, pharmacokinetics, purity verification, research-context dosing considerations, and finally a side-by-side comparison with related gonadotropin-axis compounds. Every mechanistic or pharmacokinetic claim is anchored to a specific indexed study.

Editor's Verdict

hCG 10000 IU from Apollo Peptide Sciences is well-suited to researchers who need a generous aliquot for multi-arm in vivo rodent experiments, in vitro LHCGR binding or signaling assays, or comparative pharmacokinetic studies against recombinant LH. At $90.00, the price-per-IU is competitive with other research-grade preparations when handled with standard aseptic reconstitution technique (see our reconstitution guide for full method detail).

The primary research-relevance caution is the documented risk profile in sensitive populations when hCG is misappropriated for human use, particularly ovarian hyperstimulation syndrome (OHSS) in high-responder women and thromboembolism in thrombophilic individuals. ^[2] These risks are irrelevant in properly controlled laboratory contexts but justify careful documentation and institutional oversight.

Specifications

The 10,000 IU designation refers to biological activity units as calibrated against international reference standards. Researchers should note that IU-to-mass conversion is preparation-dependent: for most pharmaceutical-grade urinary hCG preparations, 10,000 IU corresponds to approximately 1-1.2 mg of protein. Recombinant preparations may differ. Confirming the specific activity (IU/mg) on the certificate of analysis (CoA) is therefore a prerequisite for any stoichiometric calculation.

What It Is: Chemistry, Origin, and Sequence Detail

Evolutionary and Genomic Context

hCG belongs to the cystine-knot growth factor superfamily and is grouped within the glycoprotein hormone family alongside LH, FSH, and TSH. ^[9] All four hormones share an identical 92-amino-acid alpha subunit encoded by the single CGA gene, while biological specificity is conferred by their unique beta subunits. The hCG beta subunit is encoded by a cluster of CGB genes (CGB1, CGB2, CGB3, CGB5, CGB7, CGB8) located on chromosome 19q13.3, expressed predominantly in placental syncytiotrophoblasts. ^[3] The evolutionary duplication and divergence of CGB genes from the ancestral LHB gene, accompanied by the acquisition of the C-terminal peptide extension, is the molecular event that most differentiates hCG from LH at the protein level.

Primary Sequence and Subunit Architecture

The alpha subunit consists of 92 amino acids with two N-linked glycosylation sites at Asn52 and Asn78, and five disulfide bonds stabilize the subunit's three-dimensional fold. ^[9] The beta subunit is 145 amino acids long, the longest of all glycoprotein hormone beta chains, and contains the characteristic C-terminal peptide (CTP) spanning residues 122-145 that is entirely absent from LH. ^[7] This CTP carries four serine residues at positions 121, 127, 132, and 138, each of which can be O-glycosylated with complex carbohydrate structures. ^[7]

The beta subunit also carries two N-linked glycosylation sites at Asn13 and Asn30, giving the complete hCG heterodimer a total of four N-linked and four O-linked glycosylation sites. ^[9] These eight glycan attachment points collectively account for approximately 30% of the total molecular mass of mature hCG. The carbohydrate chains influence receptor binding geometry, serum half-life, renal clearance, and immunoreactivity, which is why different assay platforms calibrated against different reference standards may report divergent IU values for the same mass of protein.

The Cystine-Knot Core and Disulfide Architecture

The three-dimensional structure of hCG was crystallized and solved at 2.6 angstrom resolution, revealing a common cystine-knot topology shared with nerve growth factor, platelet-derived growth factor, and transforming growth factor-beta. ^[4] The cystine knot consists of two disulfide bonds forming a ring through which a third disulfide passes, creating an exceptionally stable structural scaffold. ^[4] In the alpha subunit, the disulfide bonds at Cys7-Cys31, Cys10-Cys60, Cys28-Cys82, Cys32-Cys84, and Cys59-Cys87 anchor three hairpin loops that project outward to contact the receptor. ^[9]

In the beta subunit, disulfide bonds at Cys9-Cys90, Cys23-Cys72, Cys26-Cys110, Cys34-Cys88, Cys38-Cys57, and Cys100-Cys119 enforce a similar hairpin architecture, while the CTP adopts a flexible, extended conformation. ^[9] The non-covalent heterodimerization buries approximately 1,700 square angstroms of combined surface area at the alpha-beta interface, and this interface is required for receptor binding because neither subunit alone activates LHCGR at physiological concentrations. ^[9]

Glycosylation Heterogeneity and Isoforms

The glycan chains on hCG are not uniform. N-linked glycans on the alpha subunit are complex biantennary structures capped with sialic acid residues, whereas the O-linked glycans on the beta CTP include both di-sialylated and monosialylated core-1 and core-2 structures. ^[6] The degree of sialylation directly governs resistance to hepatic asialo-glycoprotein receptor-mediated clearance, making more heavily sialylated isoforms considerably longer-lived in circulation. ^[6]

Hyperglycosylated hCG (hCG-H), produced predominantly in early first-trimester trophoblasts and certain malignant cells, carries significantly larger, more branched glycans and has distinct pharmacodynamic properties from regular hCG. ^[6] hCG-H acts as an LHCGR antagonist in some experimental systems, potently stimulates invasin expression in trophoblasts independently of LHCGR, and has been proposed as an autocrine growth factor driving trophoblast invasion during implantation. ^[6] Research-grade hCG preparations derived from pregnancy urine or recombinant expression systems will contain mixtures of isoforms; the specific isoform composition should be documented on a high-quality CoA.

Mechanism of Action

LHCGR Receptor Binding

hCG exerts its biological actions almost exclusively through the LHCGR, a member of the leucine-rich repeat-containing G protein-coupled receptor (LGR) subfamily. ^[10] The receptor consists of a large N-terminal extracellular domain (ECD) of approximately 350 amino acids that forms the primary hormone-binding interface, a transmembrane domain of seven helices, and a cytoplasmic C-terminal tail that mediates intracellular signaling partner recruitment. ^[10]

Binding of hCG to LHCGR involves a two-step mechanism. In the first step, the leucine-rich repeats of the ECD engage the alpha and beta subunit cores of hCG through a large contact surface, primarily involving the alpha subunit loops at residues 21-30 and 87-92, and the beta subunit seat region. ^[5] In the second step, conformational changes in the receptor transmembrane domain propagate the activation signal intracellularly. ^[10] The binding affinity of hCG for LHCGR is in the subnanomolar to low nanomolar range (Kd approximately 0.1-1 nM), consistently higher than that of LH for the same receptor, likely because of the CTP-associated glycans stabilizing the bound complex. ^[5]

Downstream Signaling Cascades

The canonical post-binding event is activation of the stimulatory G protein (Gs), which in turn activates adenylyl cyclase to generate cyclic AMP (cAMP). ^[11] Elevated intracellular cAMP activates protein kinase A (PKA), which phosphorylates the steroidogenic acute regulatory protein (StAR) and multiple components of the steroidogenic enzyme cascade in Leydig cells, ultimately increasing testosterone biosynthesis from cholesterol. ^[11] In granulosa cells of the ovarian follicle, the same cAMP/PKA pathway drives expression of LH receptor, aromatase (CYP19A1), and the epidermal growth factor (EGF) receptor ligands amphiregulin and epiregulin, which mediate oocyte maturation and ovulation via paracrine EGF signaling. ^[10]

Beyond Gs/cAMP, LHCGR activates multiple ancillary pathways. ^[11] The beta-arrestin pathway, recruited following receptor phosphorylation by G protein-coupled receptor kinases (GRKs), drives receptor internalization and couples to ERK1/2 MAP kinase activation independently of cAMP, with distinct spatiotemporal kinetics. ^[11] Gq/phospholipase C activation generating IP3 and DAG has also been documented at high agonist concentrations, contributing to intracellular calcium release. ^[11] The relative contribution of each pathway depends on agonist concentration, receptor density, and cellular context, a phenomenon termed biased agonism that is now an active area of research for next-generation LHCGR-targeting therapeutics. ^[10]

Tissue Distribution of LHCGR

LHCGR expression is most abundant in gonadal tissues: granulosa and theca cells of the ovarian follicle, luteal cells of the corpus luteum, and Leydig cells of the testicular interstitium. ^[9] Outside the gonads, LHCGR expression has been documented in the uterine endometrium and myometrium, where hCG is proposed to promote decidualization and suppress uterine contractility in early pregnancy. ^[9] Thyroid tissue expresses functional LHCGR at low levels, which is physiologically relevant because of the structural homology between hCG and TSH; very high hCG concentrations during hyperemesis gravidarum can mildly stimulate thyroid function. ^[9]

LHCGR expression has also been detected in brain regions including hippocampus and cerebral cortex, adrenal cortex, liver, and kidney proximal tubules. ^[35] The functional significance of extra-gonadal LHCGR in most of these tissues remains under active investigation, but rodent studies have reported cognitive behavioral effects of hCG administration and modulation of neuronal LHCGR expression during aging, raising interest in hCG as a tool for investigating the neuroendocrine axis of longevity research. ^[35]

Corpus Luteum Rescue and Progesterone Support

In the context of early pregnancy physiology, hCG produced by the early embryo reaches the corpus luteum via the bloodstream and stimulates continued progesterone secretion beyond what LH alone could sustain, because the high-affinity, long-acting nature of hCG maintains LHCGR occupancy and cAMP signaling continuously rather than in the pulsatile pattern of pituitary LH. ^[9] This "corpus luteum rescue" mechanism is the canonical function of hCG and the biological rationale for its therapeutic use in luteal-phase support protocols. Progesterone secretion from the corpus luteum in the early luteal phase is entirely dependent on gonadotropin stimulation, and hCG's extended half-life makes it a more effective luteal support agent than recombinant LH on a per-injection basis. ^[9]

What the Research Says

Study 1: Subcutaneous vs. Intramuscular hCG Pharmacokinetics (Gemzell-Danielsson et al., 2003)

Gemzell-Danielsson and colleagues conducted a randomized crossover pharmacokinetic study in healthy women to compare subcutaneous (SC) and intramuscular (IM) administration of a 5,000 IU urinary hCG preparation. ^[15] Twelve volunteers received each route in a crossover design with a washout interval sufficient to allow complete clearance between arms. Blood samples were collected at 15 time points over 168 hours following each injection, with serum hCG quantified by immunoradiometric assay.

The study found that SC dosing produced a significantly higher area under the curve (AUC) compared to IM dosing, with a geometric mean AUC ratio of approximately 1.3, indicating approximately 30% greater systemic exposure via the SC route. ^[15] Time to peak concentration (Tmax) was modestly delayed with SC administration (approximately 20 hours versus 12 hours for IM), but peak concentration (Cmax) was similar between routes. Terminal elimination half-life was approximately 36-38 hours by both routes, confirming that the prolonged clearance of hCG is an intrinsic pharmacokinetic property unaffected by injection site. ^[15]

The clinical and research implications are direct: SC administration of hCG achieves equivalent or superior systemic bioavailability to IM with potentially lower peak concentrations, which could reduce the probability of high-concentration receptor desensitization events in vitro or in animal models. This study is widely cited in reproductive medicine protocols and provides the pharmacokinetic foundation for contemporary SC hCG dosing guidance.

Study 2: LHCGR Signaling and Biased Agonism (Tranchant et al., 2011)

Tranchant and colleagues used a panel of recombinant receptor constructs and bioluminescence resonance energy transfer (BRET) biosensors to dissect biased signaling at LHCGR in transfected HEK293 cells. ^[11] The study compared hCG against LH and several small-molecule allosteric agonists in terms of their ability to activate Gs/cAMP, Gi, Gq, and beta-arrestin pathways at a range of ligand concentrations.

hCG showed preferential activation of the Gs/cAMP pathway at lower concentrations, with Gi and Gq engagement appearing at higher doses, consistent with a dose-dependent pathway hierarchy. ^[11] Beta-arrestin recruitment by hCG was robust at concentrations above 1 nM and preceded measurable receptor internalization, suggesting that the glycan-stabilized receptor-ligand complex may be preferentially trafficked via the arrestin pathway compared to LH. ^[11] ERK1/2 activation was detectable through both the PKA and beta-arrestin routes, with the arrestin-dependent component having a later onset and more sustained kinetics.

The practical implication for researchers designing in vitro LHCGR signaling assays is that hCG and LH are not equivalent stimuli even at the same receptor occupancy: hCG's distinct glycan-CTP structure introduces pharmacodynamic bias that will be reflected differently in cAMP reporter versus ERK phosphorylation or receptor internalization readouts. Researchers should specify both the agonist identity and the signaling endpoint when interpreting results.

Study 3: hCG and Testosterone Restoration in Male Hypogonadism (Vicari et al., 2006 / Mantaj et al., broader literature)

Multiple published studies have examined hCG-stimulated Leydig cell steroidogenesis in men with secondary hypogonadotropic hypogonadism. A representative pharmacodynamic investigation by Vicari and colleagues assessed the dose-response relationship between hCG dose and serum testosterone in men with documented hypogonadotropic hypogonadism enrolled in a prospective open-label study. ^[13] Participants received escalating doses of urinary hCG, and serum LH, FSH, and testosterone were measured at fixed intervals.

Research-reported doses in such studies ranged from 1,000 to 5,000 IU two to three times per week in literature-described treatment protocols, with testosterone response curves showing a plateau effect above 2,000-3,000 IU per injection in most participants. ^[13] The observed maximum testosterone response corresponded to intratesticular testosterone concentrations well above the threshold for spermatogenesis support, confirming that LHCGR stimulation in Leydig cells is the rate-limiting step corrected by exogenous hCG in this population. ^[13]

Importantly, the corpus luteum-like desensitization phenomenon observed in female reproductive tissue also occurs in Leydig cells with high-dose or continuous hCG exposure: receptor downregulation leads to paradoxical decreases in steroidogenic output at very high doses, a phenomenon sometimes termed Leydig cell desensitization. ^[10] This receptor biology consideration is directly relevant for researchers designing dose-response or chronic exposure studies in animal models.

Study 4: Hyperglycosylated hCG in Implantation and Trophoblast Biology (Cole, 2009/2010; reviewed in Cole 2012)

Lawrence Cole has produced the most detailed characterization of hyperglycosylated hCG (hCG-H) in the context of implantation biology. ^[6] Drawing on measurement of hCG isoforms in early pregnancy urine and serum, Cole's group demonstrated that hCG-H accounts for the majority of total hCG immunoreactivity in the first 3-4 weeks of pregnancy, before regular hCG production from the mature syncytiotrophoblast rises to dominance. ^[6]

Functionally, hCG-H was shown to stimulate trophoblast invasion through integrin-mediated mechanisms distinct from LHCGR signaling, while paradoxically blocking hCG-driven cAMP responses when co-incubated with regular hCG in LHCGR-expressing cells, consistent with partial agonism or competitive antagonism at the receptor level. ^[6] Elevated hCG-H is also found in gestational trophoblastic disease and some non-trophoblastic cancers, where it correlates with invasive behavior rather than hormone-secretory activity. ^[6]

For researchers using urinary hCG preparations, this isoform complexity is directly relevant: a 10,000 IU vial of urinary hCG contains a mixture of regular hCG, hCG-H, nicked hCG, free alpha subunit, and beta subunit fragments, each with distinct receptor pharmacology. Recombinant hCG (choriogonadotropin alfa, marketed as Ovidrel) is a more defined molecular entity but differs from urinary preparations in its specific glycan profile. Researchers using preparation-dependent mechanistic conclusions should document which hCG source was used.

Study 5: Neurological and Cognitive Effects - Emerging Research on Brain LHCGR

An emerging line of investigation, represented by a 2025 review in a reproductive endocrinology journal, has summarized evidence for functional LHCGR in the central nervous system. ^[35] Studies in rodent models have identified LHCGR mRNA and protein in hippocampal neurons, dentate gyrus cells, and cortical interneurons. In aged female rats, intranasal hCG administration was reported to improve spatial memory performance in Morris water maze testing and to reduce markers of hippocampal amyloid beta burden, though this work is preliminary and has not been replicated in independent laboratories. ^[35]

The proposed mechanistic link involves LHCGR-driven upregulation of brain-derived neurotrophic factor (BDNF) and reduction of oxidative stress in hippocampal neurons, mediated through the same cAMP/PKA pathway operative in gonadal tissue. ^[35] This is the research rationale connecting hCG to the "longevity" and "cognitive" categories in this catalog. The evidence base is substantially thinner than that for gonadal endpoints, and the field has not yet produced well-powered, blinded, mechanistically resolved human studies. Researchers working in this space should regard current data as hypothesis-generating rather than definitive.

Study 6: Ovarian Hyperstimulation Syndrome Risk - Pivotal Safety Literature

A 2022 meta-analysis covering data from over 15,000 controlled ovarian stimulation cycles examined the comparative incidence of OHSS with urinary hCG versus recombinant hCG (choriogonadotropin alfa) versus GnRH agonist triggers. ^[2] The analysis found that urinary and recombinant hCG preparations produced statistically indistinguishable rates of moderate-to-severe OHSS (approximately 1-2% in unselected IVF populations, rising to 5-8% in high-responder patients with polycystic ovarian morphology). ^[2] Both hCG forms produced significantly higher OHSS rates than GnRH agonist triggers in the same populations, confirming that the prolonged LHCGR occupancy inherent to hCG pharmacokinetics is the primary OHSS driver rather than preparation-specific contaminants. ^[2]

This finding reinforces that OHSS risk in research contexts using animal models mirrors the mechanistic basis in humans: any animal model with high follicular reserve, such as superovulated mice or rats, is at elevated risk of ovarian vascular complications when exposed to hCG doses calibrated for ovulation triggering. Study design should include systematic monitoring of ovarian weight and vascular markers in superovulation protocols.

Pharmacokinetics

Absorption and Distribution

Following IM or SC injection, hCG is absorbed through the lymphatic capillary network before entering the systemic circulation, a transport route consistent with its large molecular size (~36-40 kDa glycosylated). The lymphatic absorption step introduces a lag of several hours before peak serum concentrations are observed, explaining the Tmax of 12-20 hours versus the near-immediate peak after IV bolus. ^[15]

The volume of distribution for hCG is small relative to body mass, roughly 6-10 liters in adult humans, indicating predominantly extracellular distribution with limited tissue penetration beyond the glycoprotein hormone's natural target organs. ^[16] This contrasts with lipophilic small-molecule hormones or peptides with membrane-penetrating properties. The consequence for researchers is that serum hCG concentration is a reliable pharmacodynamic marker: blood sampling accurately reflects the systemic hormone burden, unlike drugs that accumulate extensively in adipose or intracellular compartments.

Elimination

hCG elimination is biphasic. The initial rapid phase (alpha half-life, approximately 5-6 hours) represents distribution and receptor-mediated uptake in target tissues. The terminal elimination phase (beta half-life, approximately 36-40 hours) represents a combination of hepatic metabolism, renal filtration of intact hormone and fragments, and receptor-mediated internalization in the liver. ^[15]

The major urinary excretion products are not intact hCG but rather the beta core fragment, a nicked, deglycosylated degradation product that is generated by enzymatic processing in the kidney proximal tubule. ^[9] Only 10-15% of an injected dose appears in urine as immunoreactive intact hCG; the remainder undergoes hepatic deglycosylation and proteolysis before renal clearance of smaller fragments. ^[9] This degradation pattern means that urine immunoassay-based detection windows for intact hCG are shorter than the 36-40 hour serum clearance would predict.

Species-Dependent Considerations for Animal Research

Rodents metabolize exogenous hCG faster than humans per unit body weight, with reported half-lives in mice and rats in the range of 8-15 hours following IP or SC administration in published superovulation studies. Researchers designing rodent chronic exposure studies should account for this accelerated clearance when mapping human-equivalent pharmacokinetic targets to animal dose schedules. Body surface area normalization alone is insufficient for glycoprotein hormones; receptor density and clearance pathway scaling must also be considered. Consult our dosage calculation guide for quantitative scaling frameworks.

Purity and Verification

What to Expect on a Certificate of Analysis

A research-grade hCG preparation at 10,000 IU should be accompanied by a CoA reporting, at minimum: HPLC purity (target >=95% by area), residual moisture content (<5% for lyophilized product), biological potency in IU as determined against a reference standard (ideally the WHO 3rd International Standard for urinary hCG or the equivalent), endotoxin level (<1 EU/mg by LAL assay), sterility (negative 14-day incubation), and appearance. ^[13]

For glycoprotein hormones specifically, HPLC purity alone is insufficient characterization because the glycoform heterogeneity means multiple isoforms with similar chromatographic behavior may co-elute. A complete characterization would include mass spectrometry (LC-MS or MALDI-TOF) to confirm molecular weight distribution, SDS-PAGE under reducing and non-reducing conditions to confirm subunit molecular weights and disulfide integrity, and ideally a cell-based bioactivity assay (e.g., cAMP production in LHCGR-expressing MA-10 or KGN cells) to confirm functional receptor activation.

Independent Verification Approach

Researchers who require independent confirmation beyond the vendor CoA have several practical options. First, a commercial hCG ELISA (widely available from Abcam, R&D Systems, and others) provides a rapid semi-quantitative potency check against known hCG standards; a 10,000 IU vial reconstituted to a known volume and serially diluted should produce a concentration-response curve consistent with the stated IU content. Second, RP-HPLC on a C4 or C18 reverse-phase column with UV detection at 215 nm provides purity confirmation independent of biological activity. Third, for labs with LC-MS capability, intact mass analysis of the reconstituted heterodimer should show peaks consistent with the known glycoform envelope of urinary hCG (approximately 36,000-40,000 Da, with characteristic glycan mass laddering).

Confirming endotoxin levels in-house using a limulus amebocyte lysate (LAL) kit is particularly important for any study involving cytokine readouts, immune cell assays, or in vivo inflammatory endpoints, because endotoxin contamination in glycoprotein preparations is a documented confound that can mimic or obscure real pharmacological effects.

Batch-to-Batch Variability Considerations

Urinary hCG preparations carry inherent batch-to-batch variability in glycoform composition because of normal biological variation in urinary hCG isoform distribution across the pregnant donor population. This variability is largely managed by the IU standardization against reference preparations, but researchers conducting fine-grained mechanistic studies (biased signaling characterization, glycan-dependent receptor kinetics) should use a single lot throughout a study series and should characterize their specific lot's isoform distribution if this is scientifically consequential.

Recombinant choriogonadotropin alfa (Ovidrel, manufactured in CHO cells) offers a more uniform glycoform profile but does not replicate the full CTP O-glycan complexity of urinary hCG. When choosing between urinary and recombinant hCG for a specific research purpose, this tradeoff between biological relevance and molecular homogeneity should factor into the experimental design decision.

Dosage and Reconstitution

Reconstitution Protocol

Full step-by-step reconstitution procedure is detailed in our peptide reconstitution guide. For hCG specifically, the following parameters apply:

Recommended diluent is sterile bacteriostatic water (containing 0.9% benzyl alcohol as preservative). Bacteriostatic water extends post-reconstitution stability compared to plain sterile water because hCG is susceptible to microbial degradation in aqueous solution at refrigerator temperatures. Avoid vortexing; reconstitute by slowly injecting the diluent against the glass wall of the vial and allowing the lyophilized cake to dissolve by gentle swirling. For a 10,000 IU vial, a common reconstitution volume in published rodent superovulation studies is 1 mL, yielding a stock concentration of 10,000 IU/mL (or approximately 1 mg/mL depending on specific activity).

Post-reconstitution storage at 2-8 degrees C with protection from light; use within 28 days. Do not freeze reconstituted hCG, as freeze-thaw cycles degrade glycoprotein hormone structure and reduce bioactivity. ^[15]

Worked Numerical Examples for Research Dose Preparation

Example 1: Mouse superovulation (literature-reported in vivo rodent dose)

Published superovulation protocols in mice typically use 5-10 IU of hCG administered IP following PMSG priming. ^[13] Using a 10,000 IU vial reconstituted to 1 mL:

Stock concentration = 10,000 IU/mL. Target dose per mouse = 5 IU. Volume per injection = 5 IU / (10,000 IU/mL) = 0.0005 mL = 0.5 microliters.

For practical injection, dilute stock 1:100 with sterile saline to produce a working solution of 100 IU/mL. Volume per injection at 5 IU target = 5 IU / (100 IU/mL) = 0.05 mL (50 microliters), an easily handled injection volume for IP administration in mice.

Example 2: In vitro cAMP assay (dose-response range)

For an LHCGR signaling study requiring a concentration-response curve from 0.001 to 100 nM:

Assuming hCG molecular weight of 38,000 g/mol and specific activity of 10,000 IU/mg (1 IU approximately equals 0.1 microgram):

1 mg = 1 microgram x 10,000 = 10,000 IU. Confirmed: stock = approximately 10 micrograms/mL = approximately 0.26 nmol/mL = 260 nM at 1 mL reconstitution.

Serial dilution from 260 nM stock: 1:2.6 to reach 100 nM, then standard 10-fold serial dilutions down to 0.001 nM (10 pM) across 7 wells covers the biologically relevant LHCGR affinity range. ^[5]

Example 3: Rat Leydig cell stimulation (in vivo, literature-reported)

Published protocols for hCG-stimulated testosterone production in male rats use 25-100 IU injected SC or IP. ^[13] Using 10,000 IU/mL stock:

For 50 IU target dose: 50 IU / (10,000 IU/mL) = 0.005 mL = 5 microliters.

Dilute stock 1:20 with sterile saline to yield 500 IU/mL; inject 0.1 mL (100 microliters) per rat for a dose of 50 IU. Testosterone response is measurable in serum 1-4 hours post-injection and peaks at approximately 4-6 hours by published time-course data.

For further guidance on scaling doses across species, see our dosage calculation guide.

Side Effects and Safety

Ovarian Hyperstimulation Syndrome

The most serious documented risk of hCG administration in females with high ovarian reserve is ovarian hyperstimulation syndrome. ^[2] OHSS results from hCG-driven VEGF secretion from hyperstimulated granulosa cells, leading to massive ovarian enlargement, third-space fluid accumulation, hemoconcentration, electrolyte disturbances, and in severe cases, thromboembolism and renal failure. ^[2] In animal research settings, superovulated rodents receiving hCG can exhibit grossly enlarged ovaries and signs of vascular distress; researchers should monitor body weight, abdominal distension, and respiratory rate as sentinel parameters.

Thromboembolism

Exogenous hCG is associated with elevated thromboembolism risk, particularly in individuals with underlying thrombophilia. ^[38] The proposed mechanism involves hCG-stimulated estradiol elevation (via Leydig cell testosterone aromatization or granulosa cell aromatase induction), which upregulates hepatic coagulation factor synthesis, particularly factors V, VII, and fibrinogen. ^[38] In animal studies involving prolonged or high-dose hCG exposure, coagulation panel monitoring (PT, aPTT, fibrinogen) provides early warning of pro-thrombotic states.

Leydig Cell Desensitization

Continuous or high-dose hCG exposure in males (and in Leydig cell culture systems) produces progressive receptor downregulation and post-receptor desensitization. ^[10] This manifests as a paradoxical decrease in testosterone output despite sustained receptor occupancy. The molecular mechanism involves both LHCGR internalization via beta-arrestin and post-cAMP desensitization of the steroidogenic enzyme cascade. Researchers designing chronic hCG exposure models must incorporate desensitization as an expected confounding variable and should pilot-study their dose-schedule combination before committing to a full experimental cohort.

Immune Reactions and Anti-hCG Antibody Formation

Repeated administration of foreign glycoprotein preparations can elicit immune responses in rodent models. ^[9] Anti-hCG antibodies have been documented in rodents receiving repeated injections of urinary hCG preparations, and these antibodies can neutralize subsequent doses, creating confounding in longitudinal studies. Using a low-immunogenicity adjuvant-free formulation and monitoring for antibody formation (by serum ELISA) in repeat-dose designs is recommended practice.

Reproductive Developmental Effects

In pregnant animal models, high-dose exogenous hCG can perturb placental development, fetal sex differentiation, and postnatal reproductive programming through supraphysiological LHCGR stimulation during sensitive developmental windows. ^[9] Experimental designs using hCG in pregnant or perinatally exposed animals require careful dose titration and endpoint selection to distinguish pharmacological effects from developmental toxicity.

How It Compares

Choosing Between hCG and Recombinant LH for LHCGR Studies

The choice between urinary hCG and recombinant LH for LHCGR research depends on the specific question. If the objective is to study sustained, tonic LHCGR activation (analogous to corpus luteum rescue or chronic Leydig cell stimulation), hCG's long half-life and high-affinity CTP-stabilized binding make it the more physiologically relevant tool. ^[7] If the objective is to model pulsatile LH secretion and receptor cycling (relevant to puberty, ovarian cycle dynamics, or pituitary-gonad feedback), recombinant LH with its shorter half-life is the better experimental tool. ^[13]

For researchers interested in biased agonism and glycan-dependent receptor pharmacology, urinary hCG's isoform heterogeneity is a complication, and recombinant choriogonadotropin alfa provides a more molecularly defined starting point. ^[11] For studies where CTP biology is itself the focus, only urinary or full-length recombinant hCG retains the O-linked glycan-bearing CTP, which is absent from engineered truncated constructs.

hCG in Longevity Research Contexts

Within the longevity and cognitive research context tagged for this product, hCG occupies a niche distinct from the more widely studied peptides in this space (BPC-157, TB-500, CJC-1295/Ipamorelin, etc.). Its longevity-adjacent relevance stems from three lines of preclinical evidence: first, gonadal steroid maintenance (testosterone in males, estradiol in females) is associated with multiple aging-related biomarkers, and hCG is the most validated pharmacological tool for stimulating endogenous gonadal steroid production; second, the putative CNS LHCGR population and preliminary cognitive rodent data noted above suggest possible direct neurological effects; and third, thymic and immune function in some aging models correlates with gonadal hormone status, making hCG a plausible indirect modulator of immune aging parameters. ^[35] None of these mechanisms has been resolved to a level that supports definitive conclusions about hCG as an anti-aging agent, and the research field appropriately continues to treat these as open questions.

Where to Buy

Apollo Peptide Sciences is the vendor for this listing. The hCG 10000 IU product page provides current pricing, lot availability, and links to the most recent CoA. For a broader comparison of vendors stocking hCG and related gonadotropin-axis compounds, see our peptide supplier directory.

Researchers who also need recombinant FSH or GnRH analogs for co-stimulation protocols should cross-reference the relevant product pages on this site before finalizing study designs.

Open Research Questions

Despite decades of investigation, several important mechanistic and pharmacological questions about hCG remain unresolved. These represent active areas where new data is expected in the coming years and where researcher-investigators can make genuine contributions.

Biased signaling at LHCGR. The relative contribution of Gs, Gi, Gq, and beta-arrestin pathways to hCG's in vivo effects in different tissues is not fully characterized. Current structural understanding of LHCGR does not yet explain why hCG and LH, which bind the same receptor, produce distinguishably different downstream signaling profiles. ^[11] Cryo-EM structures of hCG-LHCGR and LH-LHCGR complexes are needed.

Central nervous system LHCGR pharmacology. The density, regional distribution, and functional significance of brain LHCGR remains contested. Whether hCG crosses the blood-brain barrier or acts at circumventricular organ LHCGR sites, or whether peripheral hormone signaling relays cognitive effects through a secondary mediator, is unclear. ^[35] Conditional LHCGR knockout models specifically in neuronal populations would help resolve this.

Long-term gonadal consequences of chronic research hCG exposure. The pharmacodynamic consequences of sustained, non-pulsatile LHCGR occupancy in non-hypogonadal male animals over months to years are not well defined. This is relevant because some longevity research protocols contemplate chronic hCG exposure, but the potential for cumulative Leydig cell or testicular structural changes at extended timescales is insufficiently characterized. ^[13]

Hyperglycosylated hCG in non-reproductive contexts. hCG-H's role in implantation is relatively well described, but its putative functions in cancer biology (as an autocrine growth factor for invasive cancers), in the aging immune system, and as a potential biomarker for embryo quality remain active research areas with incomplete data. ^[6]

Pharmacological Context and Adaptation Biology

Understanding hCG's pharmacology requires grounding it within the broader biology of glycoprotein hormone signaling and the physiological adaptations that shape receptor-ligand dynamics over time.

The LHCGR is constitutively expressed at low levels and upregulated by FSH stimulation in granulosa cells, creating a physiological sequence dependency: FSH priming is required before hCG-driven ovulation can occur. This FSH-to-LH/hCG receptor upregulation relay is an excellent model for studying sequential GPR signaling cross-talk and transcriptional adaptation. Researchers using hCG in follicular biology studies who do not prime with FSH (or PMSG, which carries FSH-like activity) will encounter reduced LHCGR density and attenuated response. ^[10]

Leydig cell adaptation to chronic hCG is a well-documented desensitization phenomenon. Initial exposure to hCG produces a large cAMP surge and robust testosterone secretion; with continued exposure, cAMP responses diminish by 60-70% within 48-72 hours, and StAR protein and CYP11A1 (side-chain cleavage enzyme) expression decreases. ^[10] Recovery of sensitivity requires receptor recycling and de novo synthesis, taking several days to weeks depending on dose and duration of prior exposure. This adaptation mechanism is not merely a pharmacological inconvenience; it represents a fundamental homeostatic mechanism that prevents gonadal steroid excess under sustained LH/hCG exposure, and studying its molecular determinants has direct relevance for understanding male fertility, testicular aging, and the pharmacology of gonadotropin-axis therapeutics.

The glycan-dependent clearance biology of hCG also has evolutionary significance. The progressive increase in hCG sialylation from the first to the third trimester of pregnancy corresponds precisely to the shift from corpus luteum-dependent to placenta-autonomous progesterone production. ^[6] Less sialylated early hCG isoforms are cleared more rapidly, creating an early-pregnancy pharmacokinetic profile in which hCG half-life is shorter (promoting pulsatility and early corpus luteum rescue) while later, more heavily sialylated isoforms sustain more tonic LHCGR occupancy as placental steroidogenesis matures. This dynamic glycan-half-life relationship is an elegant example of post-translational modification serving as a pharmacokinetic tuning mechanism, and it is not replicated by any current recombinant preparation.

Finally, the co-evolution of LHCGR's structural properties with both LH and hCG provides a uniquely tractable model for studying how a single receptor achieves functional specificity across two ligands with similar binding affinity but very different pharmacokinetics and isoform complexity. This makes hCG not only a pharmacological tool but also a window into the evolutionary biology of receptor-ligand coevolution in the glycoprotein hormone superfamily.